Clinical Trials | March 12, 2024
Pfizer announces positive Phase 3 trial of ADCETRIS regimen in patients with DLBCL
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
The company intends to respond to the two minor observations within the stipulated time
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
Subscribe To Our Newsletter & Stay Updated
